Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.

Hoch, J S; Brown, M B; McMahon, C; Nanson, J; Rozmovits, L

Hoch, J S; Brown, M B; McMahon, C; Nanson, J; Rozmovits, L.

Afiliação

Hoch JS; Pharmacoeconomics Research Unit, Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; Institute for Health Policy, Management and Evaluation, University of Toronto; and Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael's Hospita
Brown MB; Department of Philosophy, University of Leth-bridge, Lethbridge, AB.
McMahon C; Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON.
Nanson J; Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON. ; Department of Psychology, University of Saskatchewan, Saskatoon, SK.
Rozmovits L; Pharmacoeconomics Research Unit, Cancer Care Ontario, and Qualitative Research, Toronto, ON.

Curr Oncol ; 21(5): 263-6, 2014 Oct.

Article em En | MEDLINE | ID: mdl-25302034

Palavras-chave

Oncology drug funding; health economics; pcodr

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google